Second-quarter 2021 sales of AstraZeneca’s Covid-19 vaccine more than tripled to $894 million from the first quarter, but the drugmaker on July 29 again delayed the U.S. application for approval as the company gathers more data for submissions.
Sanofi raised the company’s 2021 profit forecast on July 29 after its vaccines and star eczema treatment Dupixent helped the French drugmaker beat second-quarter results expectations.
Pfizer Inc. on July 28 raised the 2021 sales forecast for the company’s Covid-19 vaccine by 29 percent to $33.5 billion, and said the drugmaker believes people will need a third dose of the shot developed with German partner BioNTech to keep protection against the virus high.
Moderna Inc. is in talks with U.S. regulators to expand the size of an ongoing trial testing the company’s Covid-19 vaccines in children aged between 5 and 11 years, the drugmaker said on July 26.
A mixed vaccination of first AstraZeneca and then a Pfizer Covid-19 shot boosted neutralizing antibody levels by six times compared with two AstraZeneca doses, a study from South Korea showed.
Antibodies triggered by Sinovac Biotech’s Covid-19 vaccine decline below a key threshold from around six months after a second dose for most recipients, although a third shot could have a strong boosting effect, according to a lab study.
People who received the one-dose Johnson & Johnson Covid-19 vaccine may need a booster shot to fend off some of the worrisome coronavirus variants now spreading worldwide, a study suggests.
Moderna’s Covid-19 vaccine could become the second shot cleared for adolescent use in the European Union after regulators on July 23 recommended approving Spikevax for 12- to 17-year-olds ahead of U.S. authorities.
A longer gap between doses of Pfizer’s Covid-19 vaccine leads to higher overall antibody levels than a shorter gap, a British study found on July 23, but antibody levels are not sustained for long after the first dose.
Despite reports of a rare neurological disorder appearing in some people who have received Johnson & Johnson’s Covid-19 vaccine, the benefits of its use outweigh the risks, a U.S. Centers for Disease Control and Prevention advisory panel said on July 22.